Author Archives: KIYATEC

  • 1

NIBIB Contract: 3D Bone Marrow Mimetic

Tags : 

National Institute of Biomedical Imaging and Bioengineering (NIBIB) Awards KIYATEC $225,000 to Develop 3D Platelet Bank 

Contract Funds 3D Microbioreactor Bone Marrow Mimetic for Platelet Production

GREENVILLE, SC | September 30, 2015 – KIYATEC announced today that it has been awarded a $225,000 Small Business Innovation Research (SBIR) Phase I Grant from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), one of the 27 institutes and centers that comprise the National Institutes of Health (NIH).  Over the course of the six month award, KIYATEC will develop 3D microbioreactors useful for the in vitro production of platelets and advance its technology around bone marrow models.  Bone marrow has important implications for the company’s focus in 3D cancer assays, especially with respect to immuno-oncology models combining cancer and the human immune system.  In collaboration with Tufts University’s biomaterial scaffold design and fabrication expertise, KIYATEC will develop a perfusion bioreactor system containing a live bone marrow mimetic capable of generating clinically relevant quantities of platelets from initial bone marrow precursor cells and then characterize their morphology and function.

3D Bone Marrow Mimetic

  • 0

KIYATEC Places 2nd @ RESI 2015 in Boston

The conference showcased 30 of the most innovative life science technology companies and winners were chosen by investors, researchers and executives vote in RESI cash.

BOSTON, MA | September 16, 2015 – KIYATEC Inc. is pleased to announce that our RESI Conference poster entitledThe Business of Accurately Predicting Drug Response of Cancer Therapeuticsplaced 2nd at the RESI Conference at the Westin Copley Place in Boston.  The field of 30 presenting companies covered a broad array of life science technologies and each conference participant was given RESI cash with which they voted on their favorite technology company.  KIYATEC’s ex vivo 3D cell culture platform is being used by numerous pharmaceutical and biotech companies to predict patient drug response using primary tumors cultured in a more clinically relevant in vitro screening approach. The platform is also being used to build out a robust clinical development pipeline to predict patient drug response. 

Poster Highlights:

• 3D cell culture techniques enable creation of clinically relevant in vitro tumor models. 
• Ex Vivo 3D (EV3D) assay platform enables development of a broad range of cancer diagnostics.
• Complex co-culture models can be created to investigate immuno-oncology (IO) drug response.
• KIYATEC is expanding our clinical development pipeline in 2016 to begin clinical trials in ovarian, breast, GBM and lung cancers.


Current genomic technologies used in precision cancer care are proving to be less effective than initially touted.  The reason for their lower effectiveness is that the presence of genomic alterations often does not correlate with results in the clinic.  The current paradigm of basing clinical therapy decisions upon genetic mutation status fails to address the key problem in the field of oncology: patient response.
To address this problem, KIYATEC has developed clinically relevant in vitro assay systems that incorporate patient-derived tumor tissues.   Our approach enables researchers and eventually, clinicians, to more effectively predict drug response in real-time in order to enhance preclinical drug candidate selection, clinical trial decision making (such as supporting adaptive trial designs) and clinical treatment regimens. 
KIYATEC is now tackling drug development issues across a broad array of cancers including ovarian, breast, lung, GBM and pancreatic.  Our assay platforms have been shown to be significantly more predictive than standard 2D cell culture techniques and when integrated upfront with traditional PDX models, can greatly enhance efficiency and lower costs. We are rapidly expanding our clinical development pipeline and plan on beginning pivotal trials in ovarian and breast cancers in 2016.

  • 0

KIYATEC 3DKUBE® Featured in Tufts Publication

Tags : 


The 3DKUBE® perfusion bioreactor from KIYATEC was recently featured in the article entitled “Long term perfusion system supporting adipogenesis”

GREENVILLE, SC | April 2, 2015 – KIYATEC Inc. is pleased to announce that our 3DKUBE® perfusion bioreactor system was used to enable long term, in vitro viability and adipogenesis by researchers at Tufts University.  The article highlights the key advantages of 3D perfusion cell culture versus standard 2D and perfused 2D cell culture methods in creating adipogenic cells from preadipocyte cultures.

The work was authored by Rosalyn D. Abbott et al and results from many years of research into 3D perfusion cell culture techniques in the labs of David Kaplan at Tufts University.  The article may be purchased online at:

Key highlights of the research include:

• 2D and 3D perfusion culture techniques supported adipogenesis of preadipocytes.
• 3D perfusion contained adipocytes that were lost in the 2D perfused cultures.
• 3D perfusion stimulated greater lipogenesis and lipolysis compared to 2D perfusion.
• 3D perfusion stimulated decreased amounts of LDH compared to 2D perfusion.
• Greater glycerol was secreted with perfusion versus static cultures.

  • 0

$2M NCI Contract To Advance Predictive Cancer Diagnostics

Tags : 

National Cancer Institute Awards KIYATEC Nearly $2M to Advance Predictive Cancer Diagnostics

Contract Funds 3D Breast Cancer, 3D Brain Cancer Micro-Tumor Development

GREENVILLE, SC | September 18, 2014 – KIYATEC announced today that it has been awarded a $1.975 million, Small Business Innovation Research (SBIR) Phase II Contract from the National Cancer Institute (NCI), one of the 27 institutes and centers that comprise the National Institutes of Health (NIH). Over the course of the two year award, KIYATEC will expand its 3D breast cancer model to address two issues at the forefront of cancer therapy strategies: 1) cancer’s interaction with the patient’s immune system (immuno-oncology) and 2) cancer’s interaction with the patient’s blood supply (angiogenesis). The award will also allow KIYATEC to broaden its technology platform beyond its current use in primary ovarian cancer and breast cancer testing and into glioblastoma multiforme (GBM), a type of brain cancer with a five year survival rate that is less than 10 percent. The funded contract has the potential to radically change the future of cancer patient care.

Predictive 3D Cancer Diagnostics